⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17036527 | 0.79 | — | — | |
| SCHEMBL17050215 | 0.73 | — | — | |
| SCHEMBL3672693 | 0.72 | — | — | |
| SCHEMBL9782451 | 0.72 | — | — | |
| SCHEMBL10061053 | 0.70 | — | — | |
| SCHEMBL16122996 | 0.69 | BRS3 (0.39) | — | |
| SCHEMBL23999388 | 0.67 | — | — | |
| SCHEMBL4353518 | 0.64 | — | — | |
| SCHEMBL17039130 | 0.64 | LOXL2 (0.47) | — | |
| SCHEMBL20376055 | 0.64 | BRS3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20180072762-A1 | ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-9828396-B2 | Alkyne compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |